Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to elucidate whether the individualized medicine based on NAT2
gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug
therapy for the pulmonary tuberculosis with isoniazid.